Breaking Through the NAMs Noise: Impact of FDA's Roadmap on NAMs for Drug Safety Testing

Webcast in collaboration with Regulatory Affairs Professionals Society (RAPS). In this session, David Pepperl L. Bruce Pearce explore the FDA’s evolving expectations for New Approach Methodologies (NAMs) and their implications for drug safety testing